Home Microbiology Selection Antibiotics for Transfected Cell inhibitor - Antibiotics chemical - iGluR inhibitor D-Cycloserine

research use only

D-Cycloserine Selection Antibiotics for Transfected Cell inhibitor

Cat.No.S1998

D-cycloserine (RO-1-9213) is an analog of the amino acid D-alanine, used as an antibiotic in the treatment of tuberculosis.
D-Cycloserine Selection Antibiotics for Transfected Cell inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 102.09

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 102.09 Formula

C3H6N2O2

 Storage (From the date of receipt)
CAS No. 68-41-7 Download SDF Storage of Stock Solutions

Synonyms RO-1-9213 Smiles C1C(C(=O)NO1)N

Solubility

In vitro
Batch:

Water : 20 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vivo
D-cycloserine (DCS) facilitates extinction of conditioned freezing to the light CS when no drug pre-exposure has occurred, but pre-exposure to DCS just prior to conditioning disrupted the facilitation of extinction effect in mice. [1] D-cycloserine (DCS) which has a high affinity for the glycine modulatory site in the NMDA receptor complex modulated memory processing in a dose-dependent manner. DCS also facilitates retention in 'senescence-accelerated mice' in which impairment of learning andmemory increases with age. [2] D-cycloserine (DCS) exhibits facilitated extinction of fear but are able to reacquire fear of that conditioned stimulus (CS) in a similar manner as saline-treated control rats. DCS-treated rats exhibits generalized extinction (i.e., they are less fearful of a non-extinguished CS) in comparison to controls. [3] D-cycloserine (DCS), an antimycobacterial agent known to cross the blood-brain barrier, binds with high affinity to this glycine modulatory site, functions as a positive modulator, and facilitates performance of learningtasks in rats. DCS appears to be a potent cognitive enhancer at doses lower than those required for antibacterial activity. [4] D-cycloserine injections (3.25, 15, or 30 mg/kg) before 30 non-reinforced light exposures dose-dependently enhances extinction but does not influence fear-potentiated startle in rats that does not receive extinction training. [5]
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/2560209/
  • [5] https://pubmed.ncbi.nlm.nih.gov/11896173/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05731323 Completed
Major Depressive Disorder
University of Calgary
 October 12 2022 Phase 1
NCT01399866 Completed
Smoking Cessation
Massachusetts General Hospital
 May 2011 Phase 3
NCT00964041 Withdrawn
Schizophrenia
Massachusetts General Hospital|National Institute of Mental Health (NIMH)
 July 2009 Phase 4
NCT01062932 Completed
Nicotine Addiction
Baylor College of Medicine|National Institute on Drug Abuse (NIDA)
 May 2009 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.